| Similar Articles |
|---|
 |
The Motley Fool
December 4, 2007
Brian Lawler |
Another Drug Deal Goes Down Canadian specialty pharma Axcan Pharma became the latest drugmaker to be acquired by a private equity group -- for $1.3 billion in cash.   |
The Motley Fool
February 15, 2005
Stephen D. Simpson |
Axcan's Got Guts While growth for this Canadian drug company is a bit sluggish, ITAX could be a major winner. Investors looking at Axcan shares should treat this stock like a hybrid biotech stock. |
The Motley Fool
December 4, 2006
Brian Lawler |
I Think Axcan, I Think Axcan This small pharma is quietly growing earnings. If it can continue to keep its spending under control, investors will continue to be rewarded. |
The Motley Fool
February 22, 2006
Stephen D. Simpson |
Axcan Kicked in the Guts The failure of a phase 3 trial puts future growth prospects for Canadian specialty pharmaceutical AxcanPharma in doubt. Investors, take note. |
The Motley Fool
August 14, 2007
Billy Fisher |
A Surging Small Cap in Canada Drugmaker Axcan reports a record third-quarter. Investors, this stock has soared more than 42% over the past 52 weeks. |
The Motley Fool
December 21, 2004
Charly Travers |
Invest With Fewer Side Effects Averse to risk? Check out these nontraditional drug companies: Biogen Idec... Elan... Salix Pharmaceuticals... Atrix Laboratories... etc. |
